Department of Pharmacology and Therapeutics /newsroom/taxonomy/term/11180/all en How to turn specific genes on and off /newsroom/channels/news/how-turn-specific-genes-and-334623 <p>Type 1 diabetes, rheumatoid arthritis, and cancer are just some of the disorders associated with specific genes not “turning on” and “turning off” as they should. By using new CRISPR/Cas9 genome editing technology, in a recent paper in <a href="https://www.nature.com/articles/s41467-021-25991-9/metrics"><i>Nature Communications</i></a><i>, </i>ƬƵ University researchers have described a new technique that scientists across the world can potentially use to explore novel ways of treating diseases associated with dysregulation in DNA methylation.</p> Fri, 05 Nov 2021 20:55:30 +0000 katherine.gombay@mcgill.ca 283400 at /newsroom Experts: FDA approves much-debated Alzheimer's drug panned by experts /newsroom/channels/news/experts-fda-approves-much-debated-alzheimers-drug-panned-experts-331414 <p>U.S. government health officials approved the first new drug for Alzheimer's disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn't been shown to help slow the brain-destroying disease. The Food and Drug Administration (FDA) said it granted approval to the drug from Biogen based on results that seemed “reasonably likely” to benefit Alzheimer's patients. (<a href="https://www.ctvnews.ca/health/fda-approves-much-debated-alzheimer-s-drug-panned-by-experts-1.5459470" target="_blank">CTV News</a>)</p> Tue, 08 Jun 2021 20:48:35 +0000 frederique.mazerolle@mcgill.ca 269362 at /newsroom Gerhard Multhaup /newsroom/gerhard-multhaup Thu, 05 Aug 2021 19:58:18 +0000 frederique.mazerolle@mcgill.ca 271819 at /newsroom Five ƬƵ teams awarded funding in new Genomic Integration program /newsroom/channels/news/five-mcgill-teams-awarded-funding-new-genomic-integration-program-331618 <p>Today Genome Quebec announced the results of its Genomic Integration Program, Human Health Stream competition. Five ƬƵ teams from a diverse array of fields were awarded funds, totaling nearly $1 million. One of the defining features of this program is the requirement that institutional applicants must also have an external non-academic partner, thus supporting program goals of stimulating the Quebec economy and encouraging the use of genomic technologies in the Quebec healthcare system.</p> Mon, 21 Jun 2021 17:23:59 +0000 frederique.mazerolle@mcgill.ca 269886 at /newsroom